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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disorder featured by infl ammation of synovial tissue, characterised by proliferation of synoviocytes, production of proinfl ammatory mediators and subsequent infi ltration of predominantly mononuclear cells. 1 2 In chronically infl amed synovial tissue, macrophages, T cells, B cells, plasma cells and mast cells are abundantly present. Although RA has often been considered predominantly a T cell mediated macrophage-dependent disease, 3 4 the importance of B cells and their products have been well recognised at present. 5 Administration of B cell depleting antibody directed to CD20 (rituximab) to patients with RA results in profound and longstanding depletion of peripheral CD20 B cells in most patients. In a signifi cant number of patients, this leads to a decrease in disease activity. 6 7 Several mechanisms through which B cells can contribute to infl ammation are proposed, like antigen presentation to T cells, and production of proinfl ammatory cytokines, chemokines and autoantibodies (eg, rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA)), 8 which can trigger immune complex-mediated responses. 9 10 Although these autoantibodies decline after rituximab treatment, this does not consistently correlate with clinical response. 11 12 Since a clear understanding of the working mechanism of rituximab is lacking, it cannot be excluded that B cell products other than cytokines and autoantibodies are important in mediating disease at the local and systemic level. One of these putative other factors are κ and λ immunoglobulin (Ig) free light chains (FLCs). FLCs are produced physiologically by B lymphocytes, plasmablasts and/ or plasma cells. It has been shown that FLCs can exhibit several biological activities like enzymatic activity, complement activation, specifi c binding activity to antigens and binding to different cell types, including mast cells. 13 Serum FLC concentrations are demonstrated to be increased in several infl ammatory diseases including asthma, rhinitis, multiple sclerosis, infl ammatory bowel disease and RA. [13] [14] [15] [16] [17] In RA, serum FLC concentrations correlate with disease activity. 14 18 In the present study, we demonstrate increased local and systemic concentrations of FLC in patients with RA. In addition, we document that downregulation of FLCs by rituximab is associated with clinical improvement.
PATIENTS AND METHODS Patients and treatment protocol
To measure local FLC concentrations in the joint, synovial fl uid (SF) was collected from 68 randomly selected patients with a clinical diagnosis of RA according to American College of Rheumatology (ACR) criteria, 19 and 24 patients with osteoarthritis (OA). Paired serum samples were collected at the same time from a subgroup of these patients with RA (11 patients). To assess presence of FLCs in or Alexa Fluor 488 goat anti-rabbit IgG (both Invitrogen, Breda, The Netherlands) for 1 h. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Invitrogen). Sections were viewed with an Eclipse TE2000-U inverted microscope (Nikon, Lijnden, The Netherlands). Images were analysed using NIS elements BR 2.3 software (Nikon) .
Statistical analysis
Differences in SF FLC concentrations between patients with RA and patients with OA were determined using a Mann-Whitney test for unpaired data. Correlations between serum and SF FLCs, serum FLC concentrations and ESR and CRP, and between changes in these parameters after treatment, were determined by Spearman correlation coeffi cient. Changes in the concentrations of FLC, IgM, IgM-RF and IgG-ACPA after treatment were analysed by a one-way analysis of variance with repeated measures after log-transformation of the data. Sphericity was tested using Mauchly's test. Greenhouse-Geisser correction was applied when sphericity could not be assumed. Student t test was used to analyse whether different methotrexate or prednisone treatment dosages infl uenced FLC concentrations at baseline. p Values were considered signifi cant when p<0.05. All analyses were performed using SPSS V.15 (SPSS, Chicago, Illinois, USA). To measure the effect of rituximab treatment on serum FLCs, another 50 patients with RA were included in an open study with a follow-up of 6 months. Patients were eligible for enrolment if they were 18 years of age or older, had a clinical diagnosis of RA according to ACR criteria 19 and failed treatment with combination(s) of disease-modifying antirheumatic drugs and/or tumour necrosis factor (TNF)-blocking agents. Patients were excluded when one of the following criteria was present: life expectancy of less than 6 months, severe uncontrolled infections, irreversible major organ dysfunction, HIV positivity, a positive pregnancy test or unwillingness to use adequate contraception for the duration of the study. The patients were treated with two infusions of 1000 mg rituximab (Roche, Woerden, The Netherlands) at day 1 and day 14. Patients were assessed for disease activity using the Disease Activity Score in 28 joints (DAS28) 20 before the start of treatment, and 3 and 6 months after start of treatment. Effi cacy end point was the response according to European League Against Rheumatism (EULAR) criteria. 21 At similar time intervals, blood was collected for the assessment of serum antibody titres, including FLCs, and the infl ammatory parameters erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). In addition, serum FLC concentrations were analysed in a non-atopic control group (n=14). All patient material collection was performed according to the local Medical Ethical Committees of the University Medical Center, Utrecht and the Academic Medical Center, Amsterdam, and all patients gave their informed consent before participation in the study.
RESULTS

Clinical and demographic features
Measurements of serum antibody titres
Total serum IgG, IgM and IgA titres were measured by immunoturbidimetry on the COBAS Integra 400/700/800 (Roche Diagnostics, Indianapolis, Indiana, USA) and nephelometry on the Immage 800 (Beckman Coulter, Fullerton, California, USA) according to the manufacturer's guidelines. Serum titres of anti-cyclic citrullinated protein antibodies of the IgG isotype (IgG-ACPA) were measured using a commercial ELISA (Immunoscan RA, mark 2; Euro-Diagnostica, Arnhem, The Netherlands), according to the manufacturer's instructions and as previously reported. 22 23 Serum titres of RF of the IgM isotype (IgM-RF) were measured using a standardised ELISA, as previously described. 23 24 Total serum or SF FLC concentrations were determined using an ELISA adapted from Abe et al 25 26 (see supplementary material for details).
Immunohistochemistry
Cryostat tissue sections were allowed to air dry at room temperature prior to tissue fi xation using cold acetone for 10 min. After subsequent air drying and washing with phosphate buffered saline (PBS), sections were blocked with PBS-Tween/3% bovine serum albumin (BSA)/3% normal goat serum for 1 h, followed by over night incubation with the following primary antibodies diluted in blocking buffer: mouse anti-human κ FLC (Fκ-C8) and mouse anti-human λ FLC (Fλ-G9) (both obtained from Dr A Solomon, University of Tennessee, Knoxville, Tennessee, USA), mouse anti-human CD138 (clone MI15; Dako Cytomation, Heverlee, Belgium) and rabbit anti-human CD20 (clone BV11; Abcam, Cambridge, UK). From each tissue, three serial sections were (double) stained for λ FLC and CD20, CD138, and κ FLC and CD20. After washing in PBS-T, tissue was incubated with Alexa Fluor 568 goat anti-mouse IgG 
FLC concentrations signifi cantly decreased over time in patients that responded (good to moderate) according to EULAR response criteria (κ: −28.6±4.2% and −22.4±6.9%, p<0.0001, and λ: −23.9±3.1% and −18.1±7.5%, p<0.0001, at 3 and 6 months, respectively). By contrast, FLC concentrations in nonresponders were not signifi cantly decreased (κ: −0.2±11.4% and +10.5±16.5%, p=0.72 and λ: +5.8±15.3% and +10.2±21.3%, p=0.91, at 3 and 6 months, respectively) ( fi gure 4B,C ).
Besides the association between clinical effi cacy based on the EULAR response criteria and changes in FLC concentrations, a decrease in serum FLC concentrations also correlated with a decrease in ESR at 3 months after start of treatment (κ: r=0.47, p=0.0006 and λ: r=0.40, p=0.0045) ( fi gure 5A,C ), as well as 6 months after start of treatment (κ: r=0.54, p<0.0001 andλ: r=0.45, p=0.0012) ( fi gure 5B,D ). Comparable correlations were found between changes in FLC and changes in CRP (κ: p=0.0047, r=0.40 and λ: p=0.027, r=0.32 at 6 months after treatment).
Different dosing of prednisone and/or methotrexate was not associated with signifi cant changes in FLC concentrations (data not shown). Furthermore, baseline serum FLC concentrations did not predict the degree of change in FLC concentrations, nor clinical outcome after rituximab treatment. κ: r=0.58, p<0.0001 and λ: r=0.52, p=0.0004) ( fi gure 2E,F ) and CRP levels (n=31, κ: r=0.63, p=0.0001 and λ: r=0.49, p=0.0048; data not shown).
Relationship between serum FLCs and disease activity markers at baseline
At baseline, serum κ and λ FLC concentrations positively correlated with disease activity scores (DAS28; κ: r=0.38, p=0.0059 and λ: r=0.30, p=0.035). Similarly, FLCs signifi cantly correlated with ESR (κ: r=0.54, p<0.0001 and λ: r=0.47, p=0.0006) and CRP (κ: r=0.40, p=0.0041 and λ: r=0.39, p=0.0052) ( fi gure 3 ).
Decrease of serum FLC concentrations after rituximab treatment correlates with disease reduction
At baseline, mean serum κ and λ FLC concentrations were 56.3±6.17 and 53.5±5.31 mg/litre (mean±SEM), respectively. κ and λ FLC concentrations signifi cantly decreased as compared to baseline at 3 months (41.6±4.35 mg/litre, p<0.001 and 42.7±4.33 mg/litre, p<0.01, respectively) and 6 months (44.0±4.83 mg/litre, p<0.001 and 43.0±4.03 mg/litre, p<0.001, respectively) after rituximab treatment ( fi gure 4A ). In addition, Figure 2 Local immunoglobulin free light chain (FLC) in synovial fl uid (SF) highly correlates with systemic FLC concentrations for κ (A) and λ (B) in patients with rheumatoid arthritis (n=11). Paired serum and SF κ and λ FLC concentrations of these individual patients are shown in (C) and (D), respectively. SF κ FLC (mg/l) and SF λ FLC (mg/l) both correlated with the systemic infl ammatory parameter erythrocyte sedimentation rate (n=48) (E and F).
group.bmj.com on August 16, 2011 -Published by ard.bmj.com Downloaded from material). Because patient data were only analysed when all data from three timepoints were available, the number of nonresponding patients became limited due to missing data at single timepoints. If all non-responding patient sera at 6 months after treatment were included, IgG-ACPA also signifi cantly decreased compared to baseline values in non-responders (IgG-ACPA: p=0.035, n=15).
DISCUSSION
In this study, we show that patients with RA have high concentrations of FLC in SF of affected joints and abundant expression of FLCs in the synovial tissue. Furthermore, increased serum FLC concentrations signifi cantly correlated with SF FLC concentrations, disease activity and markers of infl ammation (ESR and CRP). B cell depletion by rituximab treatment resulted in decreased serum FLC concentrations only in patients with RA that respond to therapy.
FLCs are produced and secreted by B cells, plasmablasts and/or plasma cells. We found considerable numbers of FLCpositive cells present in synovial tissue of patients with RA. A
Effects of rituximab treatment on total Ig levels, IgG-ACPA and IgM-RF
Alterations in serum IgM, IgG and IgA concentrations were analysed and compared to changes seen for serum FLCs. The decrease of total IgM after treatment was comparable to FLC, 18.1±3.2% and 19.5±2.7%, 3 and 6 months after treatment, respectively. In contrast to FLCs however, total IgM clearly decreased in good to moderate and non-responder patients (p<0.0001 and p=0.017, respectively) (see supplementary material). Total concentrations of IgG and IgA only slightly changed after 3 (1.95±2.5% and 0.83±2.0%) and 6 months (2.73±2.3% and 3.79±2.1%), and remained within their normal range.
Concentrations of the antigen-specifi c arthritis-related antibodies IgG-ACPA and IgM-RF, were signifi cantly different from baseline after treatment (both p<0.0001) (see supplementary material). IgG-ACPA concentrations signifi cantly decreased over time in good to moderate responders (p=0.0001) not in non-responders (p=0.66). IgM-RF concentrations also significantly decreased over time in good to moderate responders (p<0.0001) and in non-responders (p=0.016) (see supplementary consistent with previous fi ndings which also showed increased concentrations of serum FLCs in patients with RA which correlated with severity of disease and CRP. 14 18 27 In addition to stronger correlations between κ and λ FLCs and CRP, in this study we fi nd clear correlations between both FLC subtypes and ESR.
Ritixumab therapy eliminates peripheral CD20-positive B lymphocytes (mature and pre-B cells) without dramatic effects on plasma cells. Peripheral B cell depletion in patients with RA signifi cantly decreased total serum FLC concentrations. Interestingly, only good to moderate responding patients showed a signifi cant decrease of κ and λ FLC serum concentrations at 3 and 6 months after initiation of rituximab treatment compared to baseline. Serum FLC concentrations in the good to moderate responders did not always return to values found in healthy subjects, which may be explained by a continued local production in the synovial tissues. Synovial B cells and plasma cells are found in a substantial number of patients with RA, and substantial proportion of these cells colocalised with CD138 plasma cells, but not CD20 cells. Recently, we found comparable colocalisation in mucosal tissue from patients with rhinitis. 16 The number of FLC-positive cells appears to exceed the number of CD138 cells, suggesting that other cells in addition to plasma cells are positive for FLC. Additional to the substantial number of FLC-positive cells in RA synovial tissue, FLC concentrations were greatly increased in SF of patients with RA as compared to patients with OA, in which we did not observe profound FLC expression and synovial plasma cell infi ltration. Moreover, serum FLC concentrations highly correlated with SF FLC concentrations. Together, our data indicate that FLCs are abundantly produced within the infl amed synovium of patients with RA, and that changes in serum FLC concentrations refl ect changes in local FLC concentrations.
Serum FLC concentrations in patients with RA were also greatly increased compared to healthy controls. The clear correlation of both FLC subtypes and DAS28 and CRP values are concentrations, to a greater extent than IgM-RF and IgG-ACPA, could serve as a biomarker for the clinical response to rituximab therapy in RA. Further studies are needed to fully explore the role of (antigen-specifi c) FLCs in the pathogenesis of RA and its potential as therapeutic target in the treatment of disease. the reduction of CD20 B cells after rituximab treatment in tissue is much more variable compared to the (nearly complete) depletion in peripheral blood. 23 28 Moreover, even multiple cycles of anti-CD20 treatment does not return patients to an immune state in which all past cellular remnants of memory and autoimmune responses have been erased. 29 Interestingly, in contrast to the effects of rituximab treatment on serum FLC concentrations, no signifi cant changes were found in serum FLC concentrations 6 and 12 weeks after anti-TNF treatment (n=20, data not shown). This suggests that the changes seen in FLC concentrations after rituximab treatment may be part of the therapeutic action of rituximab and are not a general feature of clinical response to disease treatment.
Since plasma cells represent end-differentiated B-lineage cells and seem to be the predominant producers of FLCs, B cell depletion is likely to affect plasma cell numbers in the long term and thereby FLC production. Synovial plasma cell numbers do not differ between clinical responders and non-responders at baseline. However, a direct relationship between the decrease in synovial plasma cells and clinical improvement over time after rituximab treatment is reported. 28 Therefore, indirect depletion of synovial plasma cells may be an important mechanism by which rituximab decreases FLC concentrations. This may also include depletion of a proportion of CD38 CD138 plasmablasts, which are short-lived plasma cell precursors. Interestingly, changes in FLCs do not appear to refl ect changes in total IgG and IgA, nor autoantibody concentrations. Which cell type is the major producer of FLCs and how FLC expression is regulated at a molecular level is unknown at this moment. However, our data suggest that possibly different types of plasma cells produce complete (auto)antibodies and FLCs.
Parallel to the divert FLC responses in clinical responders versus non-responders, we found clear correlations between changes in FLC concentrations and ESR and CRP. Together this indicates that the percentage change in total κ and λ FLC serum concentrations may be an interesting measurement for the clinical response to rituximab therapy. In contrast, changes in RF and ACPA do not, or to a lesser extent, correlate with response to therapy, even though RF and ACPA are good prognostic biomarkers for RA development and progression at baseline. 12 18 30 31 Our data suggest that other B cell derived factors may be involved in RA pathology and changes in FLC may refl ect changes in disease activity and treatment effi cacy.
Future experiments have to reveal whether FLCs with antigen specifi city for synovial tissue components, such as citrullinated proteins, the Fc portion of IgG, collagen type II and proteoglycans can be identifi ed. This can be of signifi cant importance since we have shown previously that FLCs can mediate antigen-specifi c mast cell activation. 32 Mast cells are suggested to play an essential role in RA pathology. Increased numbers are detected in the synovial tissue and mast cell mediators can be found in SF of patients with RA. Moreover, associations were found with proinfl ammatory cytokines and chondrolytic enzymes at sites of cartilage erosion. [33] [34] [35] It is tempting to speculate that FLCs could contribute to infl ammation and immunopathology by triggering antigen-specifi c mast cell activation in affected joints.
In conclusion, we show that increased serum FLC concentrations observed in patients with RA correlate with increased SF FLC concentrations, disease activity and infl ammatory parameters. Besides, clinical response to rituximab treatment is accompanied with a signifi cant reduction in serum FLC concentrations. Based on these data, we propose that changes in serum FLC
